FDA says more data needed for baricitinib

The US Food and Drug Administration has turned back an application from Eli Lilly and Company for baricitinib, a candidate treatment for rheumatoid arthritis, saying that more data is needed to determine the most appropriate doses of the drug for use in patients.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United States